MediCrops is a leading research and development company based in Switzerland that develops medicinal cannabis products of the highest quality for the European market with a focus on the German-speaking region. Building on its positioning as a high-quality and integrated producer of medicinal cannabis, MediCrops is expected to benefit from the rapidly growing markets in Germany, Austria and Switzerland and gain a significant market share.

Capital increase 2022

MediCrops has a financing requirement of approximately CHF 97 million until 2025 to implement the business plan, including investments for both phases of production and financing requirements from ongoing operations.

Reports & Publications

Here you will find our investor presentations and quarterly and annual reports. 

Erfolgsfaktoren & Strategie

Success factors

MediCrops offers its customers premium quality and dependable products based on a highly integrated production process and strict product quality standards